How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,313 results for

Six Item Cognitive Impairment Test

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1301. Comparing Cognitive Behavioral Therapy, Antidepressant Medication, and Combined Treatment in Individuals With Hypochondriasis

Date : June 2006 Actual Primary Completion Date : May 2011 Actual Study Completion Date : December 2011 Resource links provided by the National Library of Medicine available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: Cognitive Behavioral Therapy (CBT) Patients in this arm only received Cognitive Behavioral Therapy (CBT). Six, 60 minute weekly sessions were followed by 4 bi-weekly sessions and 3 monthly booster sessions. Behavioral: Cognitive Behavioral Therapy (CBT (...) ) CBT is based upon the cognitive and perceptual model of hypochondriasis and incorporates established behavioral techniques. There will be six 60-minute individual sessions conducted at weekly intervals. Booster sessions of 20 to 30 minutes will be conducted at Weeks 8 and 12. The introduction of boosters will make the CBT alone and medication alone arms identical in length. Placebo Comparator: Placebo Patients only received placebo pills accompanied by medication management supportive therapy

2006 Clinical Trials

1302. The Effects of Quetiapine XR on Cognition, Mood and Anxiety Symptoms in SSRI-Resistant Unipolar Depression

, lipid screen including triglycerides, urea and electrolytes, cytokines and neuroimmune markers) will performed on each patient both at baseline (t = -7 days) and at t = 56 days. At 4 weeks, blood sample will be taken for fasting plasma glucose, HbA1c and transaminases. At baseline (-7 days) and completion (56 days) a battery of neurocognitive-impairment tests (see Appendix A) will be administered. In addition, the Hamilton Rating Scale for Depression (21-ITEM HAM-D GRID), Montgomery -Asberg (...) at nine time points: a baseline prior to treatment (t = -7 days), an assessment one week after treatment has begun (t = 7 days), two weeks after (t = 14 days), three weeks after (t = 21 days), four weeks after (t = 28 days), five weeks after (t = 35 days), six weeks after (t = 42 days), seven weeks after (t = 49 days) and after 8 weeks of treatment (t = 56 days). Evaluation of cognition, mood and anxiety, will be done blind to which time point is being measured. Basic blood work (fasting blood glucose

2007 Clinical Trials

1303. Org 24448 (Ampakine) for Cognitive Deficits in Schizophrenia

., BPRS Conceptual Disorganization item score 4) No more than "moderate" severity rating on negative symptoms (i.e., all Scale for the Assessment of Negative Symptoms global items 3) A minimal level of extrapyramidal symptoms (i.e., Simpson-Angus Scale total score 6) A minimal level of depressive symptoms (i.e., Calgary Depression Scale total score 10). Cognitive Status: Performance less than the maximum cutoff (in parentheses) for ONE of the following MCCB tests: Letter-number span (.20) Hopkins (...) impairments in schizophrenia (HHSN 27820044 1003C; P.I.: Steve Marder, M.D.). Despite advances in the safety, tolerability, and effectiveness of antipsychotic medications for the treatment of schizophrenia, many patients continue to be plagued by impairments in social and work functioning. Persons with schizophrenia commonly show deficits in a number of areas of cognition that include impairments in attention, memory, and executive functioning (the ability and organize one's behavior). Importantly

2007 Clinical Trials

1304. Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. (PubMed)

Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. Cholinesterase inhibitors with additional nicotinic activity, such as galantamine, may be useful in PD patients with dementia (PDD) since stimulation of nicotinic receptors may prevent the down-regulation that is likely to accompany cholinesterase inhibition and facilitate dopamine release in the striatum.Sixteen PDD patients (six female) with onset of cognitive impairment after at least one year (...) with parkinsonism participated in this open-label trial of galantamine. Cognitive, psychiatric, and motor symptoms were assessed before and after 8 weeks of treatment with galantamine using unstructured clinical assessment as well as rating scales including the Mini-Mental State Examination (MMSE), clock drawing test, verbal fluency and selected items from the Neuropsychiatric Inventory (NPI).Age (mean, SD) was 75.6 (5.2) years, duration of PD 13.4 (5.9), duration of dementia 2.1 (1.7) years, Hoehn and Yahr

2003 International Journal of Geriatric Psychiatry

1305. Delaying the Progression of Driving Impairment in Individuals With Mild Alzheimer's Disease

specific cognitive and behavioral dysfunctions in patients with Alzheimer's disease. The cognitive subscale comprises 11 items which measure word recall (0-10), ability to follow single and multi-step commands (0-5), constructional praxis (0-5), ideational praxis (0-5), naming objects(0-5), word recognition (0-12), orientation (0-8), comprehension of spoken language (0-5), word finding difficulty(0-5) and ability to remember test instructions (0-5). 0 = no impairment with higher scores indicating more (...) scores indicate more severe impairment. Rey Complex Figure Test [ Time Frame: baseline and 12 months ] This is a measure of visual-spatial and constructional ability as well as higher order cognitive processes including planning, organizing, and problem solving. Subjects are asked to copy a complicated drawing. 18 elements are scored from 0-2 depending on accuracy/distortion and location of the reproduction. The maximum score is 36 points. Lower scores indicate more severe impairment Trail Making

2007 Clinical Trials

1306. Learning Impairments Among Survivors of Childhood Cancer

weekly during the 3-week Home Crossover Period with the best response being used as the measurement for the test. Effectiveness of MPH in Enhancing Classroom Attentiveness, Academic Productivity, and Social Behavior Measured by The Conners' Parent Rating Scale (CPRS) Cognitive Problem/Inattention Scale. [ Time Frame: Evaluated at the end of each medication week during the Home Therapy Phase- placebo, low dose and moderate dose weeks. ] The Conners' Parent Rating Scale- Revised (S) is a measure (...) and after taking either MPH or placebo. ] Change in raw scores for the shortened version of the Conner's CPT from Baseline to Post-dose. The continuous performance test used during the in-lab trial was developed in house using SuperLab Pro v2.0 (Cedrus Corp., Phoenix, AZ). The test was modeled after Conners' CPT, but was shortened for ease of administration and evaluation of short-form sensitivity. The test is one-sixth the length of the Conners' CPT, lasting 2.33 min with 54 total targets and six

2007 Clinical Trials

1307. Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia

of cognitive impairment. Patients will meet entry criteria if they have a RBANS total score of 90 or less (one standard deviation below the normal control mean). Exclusion Criteria: History of an organic brain disease History of DSM-IV alcohol or substance abuse (within the last month), or DSM-IV alcohol or substance dependence (within the last six months). Pregnant women and women taking oral contraceptives (because of the theoretical risk of breakthrough ovulation). Current treatment with galantamine (...) Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Efficacy

2005 Clinical Trials

1308. Nicotine Treatment of Mild Cognitive Impairment (MCI)

Nicotine Treatment of Mild Cognitive Impairment (MCI) Nicotine Treatment of Mild Cognitive Impairment (MCI) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Nicotine Treatment of Mild Cognitive Impairment (...) on Aging (NIA) Information provided by: National Institute on Aging (NIA) Study Details Study Description Go to Brief Summary: The purpose of this 12-month study is to determine whether nicotine, administered in the form of nicotine patches, can improve symptoms of memory loss in some people experiencing mild memory problems (referred to in this study as "mild cognitive impairment" or MCI). Condition or disease Intervention/treatment Phase Age-Related Memory Disorders Drug: Transdermal nicotine patch

2004 Clinical Trials

1309. An evaluation of two screening tools for cognitive impairment in older emergency department patients. (PubMed)

An evaluation of two screening tools for cognitive impairment in older emergency department patients. Screening for cognitive impairment in older emergency department (ED) patients is recommended to ensure quality care. The Mini-Mental State Examination (MMSE) may be too long for routine ED use. Briefer alternatives include the Six-Item Screener (SIS) and the Mini-Cog. The objective of this study was to describe the test characteristics of the SIS and the Mini-Cog compared with the MMSE when (...) a sensitivity of 75% (95% CI = 48% to 93%) and a specificity of 85% (95% CI = 73% to 93%).The SIS, using a cutoff of impaired, is a promising test for ED use. It is short, easy to administer, and unobtrusive, allowing it to be easily incorporated into the initial assessment of older ED patients.

2005 Academic Emergency Medicine

1310. Chronic distress and incidence of mild cognitive impairment. (PubMed)

persons with dementia or MCI at baseline; follow-up data were available on 1,256 persons without cognitive impairment (95% of those eligible). At baseline, they completed a six-item measure of neuroticism (mean = 15.6, SD = 6.6), an indicator of the tendency to experience psychological distress.During up to 12 years of follow-up, 482 persons (38%) developed MCI. Risk of MCI increased by about 2% for each one unit increase on the distress scale (relative risk [RR] = 1.02; 95% CI: 1.01, 1.04 (...) Chronic distress and incidence of mild cognitive impairment. Mild cognitive impairment (MCI) is associated with increased morbidity and mortality but its development is not well understood. Here we test the hypothesis that chronic psychological distress is associated with increased incidence of MCI in old age.Participants are older persons from two cohort studies with uniform annual clinical evaluations which included detailed cognitive testing and clinical classification of MCI. We excluded

2007 Neurology

1311. Cognitive and functional neuroimaging correlate for anosognosia in mild cognitive impairment and Alzheimer's disease. (PubMed)

Cognitive and functional neuroimaging correlate for anosognosia in mild cognitive impairment and Alzheimer's disease. To investigate the correlation between anosognosia and behavioural symptoms, performance on executive tests, and frontal cortex regional cerebral blood flow (rCBF) in patients with 'amnestic mild cognitive impairment' (MCI) and mild Alzheimer's disease (AD).From a prospective Memory Clinic cohort including consecutively referred patients, age 60 years or above, and with MMSE (...) score 20 or above, 36 patients with AD and 30 with MCI were included in this study. Anosognosia was assessed using a categorical scale and discrepancy scores between patients' and relatives' reports on a 20-item Memory Questionnaire (MQ). Behavioural symptoms were assessed with Frontal Behavioural Inventory (FBI). Executive functions were examined with a range of neuropsychological tests. Tc99m-HMPAO SPECT was obtained in an unselected sample of 55 of the 66 patients, and rCBF was analysed in six

2005 International Journal of Geriatric Psychiatry

1312. Validation of short screening tests for depression and cognitive impairment in older medically ill inpatients. (PubMed)

Validation of short screening tests for depression and cognitive impairment in older medically ill inpatients. To investigate the criterion validity of the four-item Geriatric Depression Scale (GDS4) and the six-item Orientation-Memory-Concentration-test (OMC) against longer widely used screening instruments.Participants were 153 patients (aged 65 or over) admitted to four acute medical wards of a northern UK town. The validity of the GDS4 was determined using the 30-item geriatric depression (...) . There was a significant correlation between the OMC and the SMMSE (rho = -0.827, p < 0.0005).The GDS4 and OMC appear to be useful instruments for screening for depression and cognitive impairment among older medical inpatients.Copyright 2004 John Wiley & Sons, Ltd.

2004 International Journal of Geriatric Psychiatry

1313. Memory Impairment Study (Mild Cognitive Impairment Study)

cognitive decline, including development of Alzheimer's disease (AD). The Memory Impairment Study is the first such AD prevention clinical trial carried out by NIH, and will be conducted at 65-80 medical research institutions located in the United States and Canada. This study will test the usefulness of two drugs to slow or stop the conversion from MCI to AD. The trial will evaluate placebo, vitamin E, and donepezil, an investigational agent approved by the Food and Drug Administration for another use (...) , and accompany the subject to all clinic visits for the duration of the protocol. CT or MRI scans within 12 months prior to screening without evidence of infection, infarction, or other focal lesions and without clinical symptoms suggestive of intervening neurological disease. A lacune in a non-critical brain area which is not believed to contribute to the subject's cognitive impairment is permissible. Adequate visual and auditory acuity to allow neuropsychological testing. Good general health

1999 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>